早期高危宫颈癌术前新辅助化疗的临床研究  

The Clinical Research of Early High-risk Cervical Cancer in Preoperative Neoadjuvant Chemotherapy

作　　者：吴丽玲 

机构地区：[1]广东省汕尾市海丰县彭湃医院,广东汕尾516400

出　　处：《中国医药指南》2013年第10期442-443,共2页Guide of China Medicine

摘　　要：目的观察紫杉醇联合顺铂新辅助化疗方案在Ib～IIa期宫颈癌根治术前的应用疗效及安全性评价。方法选择我院自2007年1月至2009年1月治疗的按国际妇产科联盟(FIGO)分期的宫颈癌患者36例作为观察组,选择同一时期的宫颈癌患者30例作为对照组,每3周为一个治疗周期,2～3个治疗周期后,对两组的临床近期疗效、毒副反应及术后生存率进行对比分析。结果观察组与对照组的近期疗效分别为80.56%(29/36)、46.47%(14/30),两组比较差异显著(χ2=29.372,P<0.05),观察组的皮疹、周围神经炎、肌肉痛等发生率,复发率及病死率与对照组比较显著降低(P<0.05)。结论紫杉醇联合顺铂新辅助化疗方案治疗早期高危宫颈癌患者,化疗的疗效确切,耐受性好,提高了Ib～IIa期有不良因素的宫颈癌的手术成功率,具有重要的临床意义。Objective To observe the efficacy and safety evaluation for paclitaxel plus cisplatin as neoadjuvant chemotherapy in lb - IIa cervical cancer before radical masteetomy. Methods 36 eases of cervical cancer from January 2007 to January 2009 with International Federation of Gynecology and Obstetrics （FIGO） staging with cervical cancer treatment were chosen as the observation group. 30 cases the same period were chosen as the control group. 3 weeks were set as a treatment cycle. After two to three treatment cycles, the recent clinical efficacy, toxicity and survival rates of the two groups were analyzed. Result The short-term effect of the observation group and control group were 80.56% （29/36） 46.47% （14/30）, the difference was significant （y2 = 29.372,P〈0.05）. The incidence, recurrence rate and mortality for rash, peripheral neuropathy and muscle pain in the observation group had a significant reduction than the control group （P〈0.05）. Conclusions The paclitaxel plus cisplatin as neoadjuvant chemotherapy in the treatment of early high-risk patients with cervical cancer, has the exact efficacy of chemotherapy, is well tolerated and improve the surgical success rate of adverse factors in the lb - Phase IIa cervical cancer, has an important clinical significance.

关 键 词：高危宫颈癌 紫杉醇 顺铂 辅助化疗 

分 类 号：R737.33[医药卫生—肿瘤]